Spirocyclic compounds, potent CCR1 antagonists.

Bioorg Med Chem Lett

Department of Medicinal Chemistry, R&I Innovative Medicines, AstraZeneca R&D, Pepparedsleden 1, Mölndal 431 83, Sweden.

Published: March 2013

Conformationally constrained spirocycles (17-23) and (31-36) were synthesised. In vitro data revealed that these compounds are CCR1 antagonists with sub-nanomolar potency. In a functional assay 22, 23 and 36 inhibited CCR1 mediated chemotaxis with an IC50 value of 2, 2.6 and 68nM, respectively.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2012.12.095DOI Listing

Publication Analysis

Top Keywords

ccr1 antagonists
8
spirocyclic compounds
4
compounds potent
4
potent ccr1
4
antagonists conformationally
4
conformationally constrained
4
constrained spirocycles
4
spirocycles 17-23
4
17-23 31-36
4
31-36 synthesised
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!